Fortress Biotech Inc (FBIO) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

makrodimutross Oct. 4 at 8:52 PM

$FBIO $FBIOP My rough prediction for Q3 wrap now: Fortress / consolidated (in millions), ultra basic Revs: 18 COGS: 6 Dep./Am.: 1 R+D: 1.2 (Saving 6.9m from Q2 CKPT expenses) SG+A: 18.9 (Saving 19.9m from Q2 CKPT expenses) Interest Exp.: 2.5 Earnings at -11.6m Fortress looks like they will be burning approximately 10m per Q... even as they ramp EMROSI, the SG+A will also increase through DERM to a ceiling value TBD. Oaktree note has a 30 month interest only expense, From July 2024. That means in January 2027 they will need to begin payback of principal. Currently they've only drawn 35m, but can access another 15m if they're on their best behavior. There seems to be a way through this without another S-3 in the next 12 months. If my prediction is correct, FBIO will have around 65m in cash at this time, and approximately 6 quarters (1.5 years) to right the ship... and most certainly by January 2027. Wild card is the FDA curtailment, and their non-acceptance of "New NDA's" at this time.

1 · Reply

Zelltable Oct. 4 at 7:08 PM

$FBIO $FBIOP My cousin Zellchair may be questioning his entire investment and has been fickle with both preferred and common, but I am all in, baby!!! Even if waiting for preferred dividends to resume feels like waiting for Santa Clause, I don’t care! My cousin may be wasting time with his indecisiveness on these tickers, but my answer is plain and simple: FBIO and FBIOP ride or die!!

1 · Reply

Vikingsstrade Oct. 4 at 5:56 PM

$ERNA $MCK $FBIO $FOX Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

0 · Reply

LiquidThetaLEAPS Oct. 4 at 8:23 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FBIO Current Share Price: $2.75 Contracts: $FBIO April 17, 2026 $5 Calls Scale in: $0.32- $0.39 Scale out: $0.49-$0.63 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

SweepCastApp Oct. 4 at 3:19 AM

$FBIO: Unusual Options Activity Alerted CALL flow observed 1708x contracts at Strike price of $2.5 Exp on 10/17/2025 with Premium of $60K and showing BULLISH Sentiment

0 · Reply

liadanielle Oct. 3 at 3:50 PM

That article is just saying there’s a bunch of lawyers who want to get rich. It’s a class action that’ll go nowhere.$FBIO Screw the articles it’s all legal mumbo-jumbo! Once the facility is taken care of we’ll be fine.

0 · Reply

SoFiCult Oct. 3 at 2:31 PM

$FBIO I've seen a couple of negative articles pop up on this one in the past 24 hrs. But, the fact is, the CRL issued for cGMP , it is easily rectified. And even if it is not, don't forget the Fortress is not banking on just this drug, that is not how they work. If this thing drops 5% today, I'm loading up more. This is about as easy a success that I have right now. I love that we see the CRL posted these days. I have to wonder how many systems are setup to sell on just the keyword CRL, because manufacturing issues should not be treated the same as a failed drug. but that is the association people are making . ( which is good for me, so why do I care :-) )

1 · Reply

ComeOnGuys Oct. 3 at 12:54 PM

$FBIO I think this will touch 3$+ fill the gap and move sideways till management communicates their plan and date of resubmission. And after fixing their problems with their manufacturers an approval is very likely (no problems with the drug itself). FBIO will have its run, maybe not today, not tomorrow but in a few months.

1 · Reply

RandomInvestor777 Oct. 3 at 12:31 PM

$FBIO I told you guys lmao, I literally told you to sell. I got the same greed with OTLK, If they don't announce results on PM FDA day, get OUT. 80% chance of failure

3 · Reply

ChessGM Oct. 2 at 10:21 PM

$FBIO Failing twice is a disgrace. Their entire operations team should get fired.

1 · Reply

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 8:05 AM EDT - 3 days ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Oct 1, 2025, 8:00 AM EDT - 3 days ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Sep 3, 2025, 8:30 AM EDT - 4 weeks ago

Market Cap	83.31M
Revenue (ttm)	57.68M
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-79.75%
Debt to Equity Ratio	1.44

Volume	1,002,100
Avg Vol	1,090,406
Day's Range	N/A - N/A
Shares Out	29.76M
Stochastic %K	25%
Beta	1.75
Analysts	Strong Sell
Price Target	$10.50